New England Research Institutes, Inc. launches a new caliber of clinical researc

Tag : drug intermediate

WATERTOWN, Mass.--( BUSINESS WIRE )--New England Research Institutes, Inc. (NERI), is uniquelypositioned to provide a portfolio of clinical and epidemiologicalresearch services to both the private and public sectors. With this unique dual capability, NERI is launching its “ Thoughtful Science. Tailored Solutions. ” approach to client service in booth number 1341 at this year ’ s 44 th Annual Drug Information Association (DIA) Meeting in Boston. Thisintegrated process of conducting business ensures that clientsbenefit from NERI ’ s breadth of experience working on both private industry clinicaltrials as well as government-sponsored research. This flexibleoperational model is supported by an EDC platform that streamlinesprotocol details, data acquisition, real-time reports, sitemanagement, site monitoring, and more.
NERI is a global, specialty Contract Research Organization (CRO)that provides customized clinical trial solutions and patientregistry services to pharmaceutical, biotechnology, biomaterial andmedical device companies. NERI is leveraging its expertise gained during a 20-year trackrecord working on federally-funded research, with organizationslike the National Institutes of Health (NIH), to continue expandingits business into the private sector. NERI currently hasapproximately 200 professionals on staff and a mix of 65 privateand public sector clients in a variety of therapeutic areas. NERIhas recently been awarded new business in medical areas rangingfrom neurodegenerative diseases in children and urolologicalstudies to cardiovascular imaging trials.
“ As a scientifically-driven organization, NERI embraces clinicalresearch with a deep sense of integrity and passion, ” says NERI President, Sonja McKinlay, Ph.D. “ Our unique combination of private and public sector experiencegives our company an unmatched edge against industry competitors.Plus, our innovative technology systems monitor and coordinate allaspects of a study in real time, and communicate promptly withclients, ” says McKinlay.
NERI conducts domestic and international clinical trials of drug,observational studies and registries with significant capabilitiesin Phase II, Phase III, and Phase IV multi-site research. Inaddition to its North American and European depth, NERI hasestablished a consortium of strategic CRO partners in emerginglocations including Eastern Europe, Latin America, and Asia. Thesepartners are local to these specific countries and regions.
“ Clients who work with NERI reach a new level of clinical trialsuccess, ” says Vice President of Clinical Research, Rebecca Li, Ph.D. “ NERI has demonstrated abilities in the operational requirements ofmulti-center, complex clinical and health-related studies, withsensitivity to international requirements. Our exceptionalscientific depth and rich portfolio of services offer small tomid-size biotechs innovative clinical research solutions, ” says Li.
NERI scientists will chair two 90-minute sessions and one posterpresentation at this year ’ s DIA meeting. In partnership with Stuart Pocock, Ph.D., LondonSchool of Hygiene and Tropical Medicine and Janet Wittes, Ph.D.,Statistics Collaborative, Washington DC, Dr. McKinlay will conductan intermediate discussion titled, Selecting the Optimal Sample Size: Initial Realism or AdaptiveRe-estimation. In collaboration with Michael Domanski, M.D., Atherothrombosis& Coronary Artery Disease Branch Chief, National Heart Lung andBlood Institute (NHLBI) and Dean C. Winter, Ph.D., Vice President,Scientific & Clinical Affairs, AtCor Medical Inc., Dr. Li willlead an intermediate session titled, Forging Partnerships with NIH-sponsored Clinical Trials andNetworks. In addition, NERI Director of Regulatory Affairs, Flora SandraSiami, MPH, will present a poster titled, Ensuring Compliance and Quality in Global Clinical Trials.
About NERI:
Since its founding in 1986, NERI has earned widespread recognitionfor its scientific credibility, efficiency and expertise inconducting clinical trials in a variety of medical specialties. Formore information, visit www.neriscience.com .